Stroke RSS Page 18

Filtered By:
Drug: Activase

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran
CONCLUSIONS: Base-case and sensitivity analysis showed that TNK is the dominant strategy compared to ALT for the management of AIS patients.PMID:36420792 | DOI:10.1080/14737167.2023.2152008
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2022 Category: Health Management Authors: Kosar Hajian Ramin Abdi Dezfouli Ali Darvishi Ramin Radmanesh Ramin Heshmat Source Type: research

Mild and moderate cardioembolic stroke patients may benefit more from direct mechanical thrombectomy than bridging therapy: A subgroup analysis of a randomized clinical trial (DIRECT-MT)
ConclusionMild and moderate cardioembolic stroke patients may benefit more from direct mechanical thrombectomy than bridging therapy. This need to be confirmed by further prospective studies in a larger number of patients.
Source: Frontiers in Neurology - November 24, 2022 Category: Neurology Source Type: research

Effect of stroke etiology on endovascular thrombectomy with or without intravenous alteplase: a subgroup analysis of DIRECT-MT
Conclusions The results did not support the hypothesis that a specific treatment strategy based on stroke etiology should be used for patients with large vessel occlusion (NCT03469206).
Source: Journal of NeuroInterventional Surgery - November 14, 2022 Category: Neurosurgery Authors: Xing, P., Zhang, X., Shen, H., Shen, F., Zhang, L., Li, Z., Zhang, Y., Hong, B., Shi, H., Han, H., Ye, X., Zhang, Y., Yang, P., Liu, J., On behalf of the DIRECT-MT investigators Tags: Vascular neurology Source Type: research

Tenecteplase in acute ischemic stroke: Review of the literature and expert consensus from the French Neurovascular Society
CONCLUSIONS: These expert consensus statements could provide a framework to guide the clinical decision-making process for the use of tenecteplase according to admission characteristics of AIS patients. However, existing data are limited, requiring inclusions in ongoing RCTs or real-life registries.PMID:36369068 | DOI:10.1016/j.neurol.2022.08.005
Source: Revue Neurologique - November 11, 2022 Category: Neurology Authors: S Olindo J-F Albucher Y Bejot J Berge C Cordonnier B Guillon D Sablot J Tardy S Alamowitch I Sibon Source Type: research

No sex difference was found in the safety and efficacy of intravenous alteplase before endovascular therapy
ConclusionOur study could not confirm that sex modifies the treatment effect of intravenous alteplase before endovascular therapy. At the same time, we advocate for women to seek timely medical treatment.
Source: Frontiers in Neurology - November 9, 2022 Category: Neurology Source Type: research

Safety of early antiplatelet administration in patients with acute ischemic stroke treated with alteplase (SEAPT-24)
This study aimed to examine the safety of early antiplatelet therapy administration within the first 24 h after alteplase.
Source: Journal of Stroke and Cerebrovascular Diseases - November 5, 2022 Category: Neurology Authors: Drew A. Wells, Lyndsey K. Davis, Omar Saeed, G. Morgan Jones, Cheran Elangovan, Andrei V. Alexandrov, Balaji Krishnaiah, Katherine L. March Source Type: research

Combo Thrombolytic Approach Fails to Reduce ICH in Stroke Combo Thrombolytic Approach Fails to Reduce ICH in Stroke
The DUMAS study showed no benefit on the primary outcome of all ICH with low-dose alteplase followed by mutant pro-urokinase; but there were promising signs of a potential reduced bleeding risk.Medscape Medical News
Source: Medscape Cardiology Headlines - November 2, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Hidden Telltale Signs in Hyperacute Ischemic Stroke Caused by Aortic Dissection: A Case Report and Post Hoc Analysis
Conclusion: Hyperacute ischemic stroke caused by AD often hides some telltale signs. Clinicians should master basic clinical skills to exclude AD by looking for these telltale signs hidden in hyperacute ischemic stroke to avoid the fatal consequences of intravenous thrombolysis and/or cerebral angiography within the narrow window of time.
Source: The Neurologist - November 1, 2022 Category: Neurology Tags: Case Report/Case Series Source Type: research

Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke
Conclusions: Patients with increasing age, a higher baseline systolic blood pressure, and previous ischemic stroke were at a higher odd of receiving a low-dose of alteplase. The low-dose was associated with a lower risk of developing symptomatic intracranial hemorrhage.PMID:36313231 | PMC:PMC9608043 | DOI:10.7150/ijms.76105
Source: International Journal of Medical Sciences - October 31, 2022 Category: Biomedical Science Authors: Jie Chen Hangfeng Li Hanhan Lei Shuangfang Fang Qilin Yuan Yangui Chen Dongping Chen Ronghua Chen Yixian Zhang Jin Wei Guangliang Chen Zhiting Chen Nan Liu Hou-Wei Du Source Type: research

In acute ischemic stroke, thrombectomy was not noninferior to alteplase + thrombectomy for 90-d functional independence
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0088. Online ahead of print.ABSTRACTFischer U, Kaesmacher J, Strbian D, et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet. 2022;400:104-15. 35810756.PMID:36315954 | DOI:10.7326/J22-0088
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Anthony A Donato Vaibhav Goswami Source Type: research

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome
Ann Intern Med. 2022 Nov 1. doi: 10.7326/J22-0090. Online ahead of print.ABSTRACTMenon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.PMID:36315948 | DOI:10.7326/J22-0090
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Emma Ferguson Eddy Lang Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20